Abstract
Double Blind randomised controlled trials are the gold standard in estimating the clinical effect of medications, with pivotal phase 3 clinical trials forming the foundation a total revolution in healthcare decision making over recent decades. However, such trials are prohibitively expensive to conduct and the probability of a successful launch of a new medicine ranges from only 3% in nervous system disorders to 16% in anti-infectives . By considering Markov and Discrete Event Simulation models, now used extensively in post launch decision making globally, it is possible to conduct “virtual trials” at all launch phases to robustly analyse medications and their value as treatments.
References
Dowden H, Munro J. Trends in clinical success rates and therapeutic focus Nature reviews. Drug discovery vol. 18,7 (2019): 495-496
Mauskopf, J. Meeting the NICE requirements: a Markov model approach.” Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 3,4 (2000): 287-93.
- Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.
- Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.
- Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).